Dyne Therapeutics, Inc. research snapshot
DYN AI stock analysis reads Dyne Therapeutics as a high-risk, high-reward pre-commercial biotechnology company developing muscle and CNS-targeted therapies on its proprietary FORCE platform. As of the August 3, 2026 data cutoff, DYN trades near $25.07 with a market capitalization of roughly $4.68 billion, after the FDA accepted the BLA for z-rostudirsen in exon 51 DMD and granted Priority Review with a PDUFA target action date of January 21, 2027. Dyne also completed enrollment of 71 participants in the ACHIEVE registrational cohort of z-basivarsen in DM1, with topline data planned for Q1 2027, and cleared an IND for DYNE-302 in FSHD. The company ended Q2 2026 with $898.5 million in cash and marketable securities, added roughly $405 million in net proceeds from a July equity offering, and expects runway into Q2 2028. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$25.07
Market cap
$4.68 billion
AI score
55 / 100
Rating
Pre-commercial neuromuscular biotech with an FDA-accepted BLA for DMD exon 51, a DM1 registrational cohort reading out in Q1 2027, and heavy cash burn
Trend status
Strong uptrend from a 52-week low near $9.60, trading near $25.07 just below the $26.26 52-week high after a July equity offering
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Dyne is a pre-commercial biotechnology company building antibody-oligonucleotide conjugates (AOCs) for muscle and CNS diseases. Business quality is unproven until regulatory approval, commercial adoption, and revenue generation are demonstrated, though the FDA-accepted BLA is a meaningful de-risking step. | Low |
| Moat | The FORCE platform uses antibody-mediated delivery to target muscle tissue, differentiating it from unconjugated oligonucleotide therapies. If clinical and regulatory data confirm superior delivery and efficacy, the platform could support a broad pipeline across DMD, DM1, FSHD, and Pompe, though competitors such as Avidity, Sarepta, Ionis, and PepGen are pursuing overlapping targets. | Low-medium |
| Management | Management delivered the BLA acceptance with Priority Review, completed ACHIEVE registrational enrollment, started the HARMONIA and FORZETTO Phase 3 trials, cleared an FSHD IND, expanded the Hercules debt facility to $400 million, and raised roughly $405 million net in a July offering. The team should now be judged on the PDUFA outcome, commercial preparation, data quality at readout, and disciplined capital use. | Medium |
| Financial trend | Dyne has no revenue and generates GAAP net losses of roughly $108 million to $179 million per quarter, with Q2 2026 at $178.6 million. Cash and marketable securities were $898.5 million on June 30, 2026, and the company added about $405 million net from the July offering, funding operations into Q2 2028, but long-term funding still depends on capital markets. | High |
| Valuation | At $25.07 and a roughly $4.68 billion market cap, Dyne holds about $1.30 billion of pro forma cash (approximately $6.98 per share on ~186.75 million shares), implying roughly $18 per share of pipeline value. This is typical for a pre-commercial biotech with near-term regulatory catalysts but prices in meaningful success probability. | Medium |
| Technical trend | DYN has been in a strong uptrend over the past year, roughly +160%, with the stock near $25.07 just below the $26.26 52-week high. After the July offering priced at $20.50, the stock dipped toward the low $20s and recovered, leaving it above its major moving averages with momentum positive but extended. | Medium |
| Risk level | Very high. Key risks include a negative or mixed ACHIEVE topline in Q1 2027, a delayed or unfavorable PDUFA decision on z-rostudirsen, launch execution failure, safety signals, competitive pressure from Avidity, Sarepta, and Ionis, and dilution from future equity offerings given ongoing cash burn. | High |
| AI confidence | High for cash, shares, market cap, net loss, and runway from SEC filings and press releases. Low for pipeline valuation, clinical success probability, and forward price targets. | Medium overall |
| Investment certainty | Low. Dyne is a binary event-driven biotech where the outcome depends on the January 2027 PDUFA decision, the Q1 2027 DM1 data, and commercial execution that no model can predict with confidence. | Low |
DYN AI stock forecast
The DYN AI stock forecast uses scenario ranges around the $25.07 cutoff price. With a market cap of roughly $4.68 billion and pro forma cash near $1.30 billion, the market prices in about $18 of pipeline value per share above cash. The three-year framework produces a bearish area near $6 to $11 (catalyst failure, stock drifts toward cash value), a base area near $32 to $45 (z-rostudirsen approval and launch with gradual DM1 progress), and a bullish area near $55 to $75 (strong DMD launch plus a positive DM1 topline in Q1 2027 supporting a 2028 approval).
$55 to $75
More likely if z-rostudirsen launches strongly after a January 2027 approval, the ACHIEVE topline in Q1 2027 shows compelling efficacy and safety that supports a z-basivarsen BLA submission in Q3 2027, and the FORCE platform expands across FSHD and additional DMD programs, validating a platform premium.
$32 to $45
More likely if z-rostudirsen is approved on schedule with a moderate launch curve, z-basivarsen data are positive but commercial adoption is gradual, the company manages dilution within expectations, and cash discipline keeps the balance sheet funded through the 2028 runway.
$6 to $11
More likely if the ACHIEVE readout fails to meet efficacy endpoints or shows safety concerns, the z-rostudirsen launch disappoints or the PDUFA decision is delayed, regulatory setbacks occur, competitive therapies from Avidity, Sarepta, or Ionis reach the market first, or cash burn forces dilutive financing near cash value.
DYN AI technical analysis
DYN AI technical analysis shows a strong uptrend as of the August 3, 2026 data cutoff. The stock has risen roughly 160% over the past year and trades near $25.07, just below the $26.26 52-week high. After pricing a $375 million offering at $20.50 in July 2026, the stock dipped toward the low $20s and then recovered. It remains above its major moving averages with momentum positive but extended, making it sensitive to news-driven moves.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $25.07 | Google Finance quote on August 3, 2026 placed DYN just below its $26.26 52-week high. |
| Near support | $23 to $24 | Recent consolidation zone after the July equity offering and Q2 earnings, aligning with moving average support. |
| Deeper support | $20.00 to $20.50 | The July offering price zone of $20.50 has acted as a reference level; a sustained close below it would weaken the uptrend structure. |
| Near resistance | $26.26 | The 52-week high at $26.26 is the immediate technical resistance. A close above it on volume would signal trend continuation. |
| Longer-term resistance | $28 to $30 | If DYN breaks above the 52-week high, the next resistance zone is the $28 to $30 area, representing psychological levels above the current range. |
| Momentum | Positive but extended | Following the roughly +160% one-year rally, momentum indicators are likely elevated though not necessarily overbought in the context of a strong uptrend. |
| Volume | Average volume near 2.1 to 2.7 million shares | Volume spiked around the July offering and the Q2 earnings release; clinical data and FDA news can produce sharp volume bursts. |
| Volatility | High, typical for a pre-commercial biotech | DYN is a binary event-driven stock where FDA decisions, trial data, and financing announcements can produce double-digit single-day moves in either direction. |
| Invalidation | Close below $20.00 | A decisive close below the $20.00 to $20.50 support zone would weaken the uptrend structure and suggest a potential trend reversal. |
DYN AI trading strategy
The DYN AI trading strategy is a rules-based research framework for monitoring a pre-commercial neuromuscular biotech with two near-term catalysts: the z-rostudirsen PDUFA on January 21, 2027 and the ACHIEVE topline readout in Q1 2027. It is not personal advice and should be paired with current filings, clinical timelines, position sizing appropriate for high-risk biotech, and a defined invalidation level.
The z-rostudirsen PDUFA target action date of January 21, 2027 and the ACHIEVE topline in Q1 2027 are the primary catalysts. Approval with Priority Review and a strong DM1 efficacy result could trigger a substantial re-rating. A negative readout, a complete response letter, or a safety signal would likely push the stock toward cash value near $7 per share.
Position sizing must account for binary outcomes. A close below $20 or an adverse catalyst should trigger an exit. Consider using options for defined risk exposure rather than outright common stock.
If DYN breaks above $26.26 on above-average volume, the uptrend may extend toward $28 to $30. Maintain a position as long as price stays above the 50-day moving average, adjusting stops as the trend develops.
A close below $20 or a violation of the 50-day moving average should invalidate the trend-following setup. Biotech gaps can be severe, so avoid over-leveraging.
Track the z-rostudirsen PDUFA outcome and launch preparation, the ACHIEVE topline data quality, HARMONIA and FORZETTO enrollment progress, cash burn of roughly $180 million per quarter, dilution risk from equity offerings, DYNE-302 FSHD Phase 1 progress, and competitive positioning against Avidity, Sarepta, Ionis, and PepGen.
Reduce or exit if cash runway shortens without a clear funding path, if competitive therapies show superior data, if trial timelines slip, or if launch execution signals deteriorate.
Investment research summary
Dyne Therapeutics aims to deliver functional improvement for people with genetically driven neuromuscular diseases by targeting muscle and the CNS with its FORCE platform. Patients and physicians pay for disease-modifying therapy in conditions that currently have limited treatment options, including DMD, DM1, and FSHD.
The potential moat is based on FORCE platform technology for targeted muscle and CNS delivery. If validated by clinical and regulatory data, it could be applicable across DMD, DM1, FSHD, and Pompe, creating a pipeline-in-a-product opportunity. However, competitors including Avidity Biosciences, Sarepta Therapeutics, Ionis Pharmaceuticals, and PepGen are pursuing overlapping targets, so the ultimate moat depends on clinical differentiation and launch execution.
The thesis fails if the ACHIEVE DM1 readout disappoints, the z-rostudirsen launch stalls or the PDUFA decision slips, safety signals emerge, competitors reach the market first with better data, cash runs out before revenue materializes, or the FORCE platform proves less broadly applicable than hoped.
Management has delivered the FDA BLA acceptance with Priority Review, completed ACHIEVE registrational enrollment, started the HARMONIA and FORZETTO Phase 3 trials, cleared an FSHD IND, and secured a $400 million debt facility plus roughly $405 million net from a July equity offering. Key tests ahead include the PDUFA outcome, commercial execution, DM1 data quality, and disciplined capital allocation.
Dyne operates at the intersection of two important trends: the growing field of oligonucleotide therapeutics for genetic diseases and targeted delivery technologies that enable tissue-specific treatment. DMD and DM1 represent significant unmet need with large patient populations, and regulatory momentum such as Priority Review supports the broader neuromuscular disease market.
At $25.07, the stock prices in meaningful pipeline value of roughly $18 per share above a pro forma net cash value of about $6.98 per share. Margin of safety is limited because the premium depends on the January 2027 PDUFA decision and the Q1 2027 DM1 data. Historically the most favorable risk-reward occurs closer to cash value, not near 52-week highs.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| DYN price | $25.07 | Google Finance quote snapshot | August 3, 2026 |
| Market capitalization | $4.68 billion, verified as $25.07 x 186.75 million shares | Yahoo Finance market cap verification | August 3, 2026 |
| Shares outstanding | 186.75 million, after the July 2026 offering | Google Finance share count | August 3, 2026 |
| Cash, cash equivalents and marketable securities | $898.5 million as of June 30, 2026 | Dyne Q2 2026 earnings press release (GlobeNewswire) | August 3, 2026 |
| July 2026 public offering | 21,045,000 shares at $20.50, gross proceeds ~$431 million, net ~$405 million | Dyne Q2 2026 earnings press release (GlobeNewswire) | August 3, 2026 |
| Pro forma cash and runway | ~$1.30 billion after the July offering; company-guided runway into Q2 2028 | Dyne Q2 2026 earnings press release (GlobeNewswire) | August 3, 2026 |
| Q2 2026 net loss | -$178.6 million (-$1.08 per share) | Dyne Q2 2026 earnings press release (GlobeNewswire) | August 3, 2026 |
| Q2 2026 R&D expense | $152.2 million | Dyne Q2 2026 earnings press release (GlobeNewswire) | August 3, 2026 |
| TTM net loss | Approximately -$519 million (computed from quarterly statements, Sep 2025 to Jun 2026) | Google Finance income statement | August 3, 2026 |
| Debt facility | Up to $400 million from Hercules Capital (expanded June 2026) | Dyne Q2 2026 earnings press release (GlobeNewswire) | August 3, 2026 |
| 52-week range | $9.57 to $26.26 (Yahoo Finance) | Yahoo Finance price range | August 3, 2026 |
| Analyst consensus | 12 analysts: 10 Buy, 2 Hold, 0 Sell; average target $40.67, range $24 to $50 | Google Finance analyst ratings | August 3, 2026 |
| z-rostudirsen PDUFA | BLA accepted, Priority Review granted, PDUFA target action date January 21, 2027 | Dyne Q2 2026 earnings press release (GlobeNewswire) | August 3, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell DYN stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Dyne Therapeutics is a pre-commercial biotechnology company with zero revenue, negative earnings, and binary regulatory and clinical risk. Always verify current filings, FDA decisions, clinical data, cash runway, risks, and personal suitability before making financial decisions.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
